Classical PKC isoforms in cancer

被引:120
作者
Martiny-Baron, Georg [1 ]
Fabbro, Doriano [1 ]
机构
[1] Novartis Inst Bomed Res, Expertise Platform Kinases, CH-4002 Basel, Switzerland
关键词
protein kinase C; PKC inhibitors; cancer;
D O I
10.1016/j.phrs.2007.04.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Protein kinases C (PKCs) are a family of serine/threonine kinases which are involved in tumor formation and progression. Although PKC over-expression has been shown to contribute to cell transformation, PKCs are not considered to be classical oncogenes which are activated by mutations, but considered as tumor promoters that enhance multiple cellular signaling pathways. Over the last two decades a lot of evidence has emerged demonstrating a role for various PKC isoforms in cancer. Small molecular weight inhibitors and antisense molecules have been developed, specifically targeting the calcium dependent classical isoforms of PKC. This review focuses on the role of classical PKCs in cancer and the results obtained by attempting to inhibit these enzymes to achieve a therapeutic benefit. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:477 / 486
页数:10
相关论文
共 154 条
[1]   MODIFIED HIPPOCAMPAL LONG-TERM POTENTIATION IN PKC-GAMMA-MUTANT MICE [J].
ABELIOVICH, A ;
CHEN, C ;
GODA, Y ;
SILVA, AJ ;
STEVENS, CF ;
TONEGAWA, S .
CELL, 1993, 75 (07) :1253-1262
[2]   A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma [J].
Advani, R ;
Peethambaram, P ;
Lum, BL ;
Fisher, GA ;
Hartmann, L ;
Long, HJ ;
Halsey, J ;
Holmlund, JT ;
Dorr, A ;
Sikic, BI .
CANCER, 2004, 100 (02) :321-326
[3]   Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma [J].
Ainsworth, PD ;
Winstanley, JHR ;
Pearson, JM ;
Bishop, HM ;
Garrod, DR .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2269-2273
[4]   ENHANCEMENT OF ANTITUMOR-ACTIVITY OF MITOMYCIN-C INVITRO AND INVIVO BY UCN-01, A SELECTIVE INHIBITOR OF PROTEIN-KINASE-C [J].
AKINAGA, S ;
NOMURA, K ;
GOMI, K ;
OKABE, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (03) :183-189
[5]  
Akiyama T, 1997, CANCER RES, V57, P1495
[6]   G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation [J].
Akiyama, T ;
Sugiyama, K ;
Shimizu, M ;
Tamaoki, T ;
Akinaga, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (12) :1364-1372
[7]   Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01 [J].
Amornphimoltham, P ;
Sriuranpong, V ;
Patel, V ;
Benavides, F ;
Conti, CJ ;
Sauk, J ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4029-4037
[8]   PKC-β inhibition:: a new therapeutic approach for diabetic complications? [J].
Avignon, A ;
Sultan, A .
DIABETES & METABOLISM, 2006, 32 (03) :205-213
[9]  
Begemann M, 1998, ANTICANCER RES, V18, P2275
[10]   Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation [J].
Beltran, PJ ;
Fan, D ;
Fidler, IJ ;
OBrian, CA .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :245-247